E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with symptomatic ischemic heart disease expressing one or two de novo native coronary artery lesions |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10011078 |
E.1.2 | Term | Coronary artery disease |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to assess endothelial-dependent vasomotion after stenting with Genous and drug-eluting stents (Xience V) at 6 month follow-up.
The primary endpoint of this study is mean coronary segment diameter change from baseline after maximal endothelium-dependent vasomotion at 6 months post-procedure. |
|
E.2.2 | Secondary objectives of the trial |
The following secondary endpoints will be assessed: • Mean coronary segment diameter change from baseline after maximal endothelium-independent vasodilation at 6 months post-procedure (2-3 mg i.c. nitrates). • Major adverse cardiac events (MACE) and Target Vessel Failure (TVF) at 30 days, 6 and 12 months • Circulating endothelial progenitor cell (EPC) count at the index procedure and 6 months post-procedure • CFR at index procedure and at follow-up • Protocol-related serious adverse events (SAEs) up to 12 months
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Currently receiving statin therapy for at least 2 weeks prior to the index procedure; 2. 18 to 85 years of age; 3. Symptomatic ischemic heart disease (CCS class 1–4, Braunwald class IB, IC, and/or objective evidence of myocardial ischemia); 4. Single de novo lesions; Patients with an additional lesion in another vessel can be included, however, the vasomotion study is to be performed on only one lesion which is identified by the investigator, prior to randomization, as the one which is most suitable for vasomotion study. 5. Target lesion is located in a native coronary artery, which can be covered by one single; 6. Reference vessel diameter 2.5 and 4.0 mm by visual estimate; 7. Acceptable candidate for coronary artery bypass surgery (CABG); 8. Target lesion stenosis is >50% and <100% (minimum TIMI flow I at the time of the PCI procedure) (visual estimate); 9. The patient is willing to comply with the specified follow-up evaluation; 10. The patient has been informed of the nature of the study agrees to its provisions and has provided written informed consent, approved by the appropriate Ethics Committee (EC).
|
|
E.4 | Principal exclusion criteria |
1. Women who are pregnant or women of childbearing potential who do not use adequate contraception; 2. A Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure, unless the CK and CK-MB enzymes or Troponin levels are less than twice the Upper Normal Limit; 3. Uncontrolled hypertension or currently treated with three or more hypertensive medications. Patients unable to discontinue beta blockers, calcium antagonists, nitrates, ACE inhibitors or angiotensin II inhibitors for 48 hours prior to the scheduled 6 month angiographic follow-up should not be included. 4. Impaired renal function (creatinine > 3.0 mg/dl or 265 µmol/l); 5. Any patient who has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3 or a WBC of < 3,000 cells/mm3; 6. Documented or suspected liver disease (including laboratory evidence of hepatitis); 7. Recipient of heart transplant; 8. Any patient who previously received murine therapeutic antibodies and exhibited sensitization through the production of Human Anti-mouse Antibodies (HAMA); 9. Patient with a life expectancy less than the follow-up period (6 months); 10. Known allergies to aspirin, clopidogrel bisulphate (Plavix) and ticlopidine (Ticlid), heparin, or stainless steel; 11. Known side-effects (clinically demonstrated by biological tests, elevated CK and liver assessments) to statins and previous attempts to treat side-effects were unsuccessful; 12. Any significant medical condition which in the Investigator’s opinion may interfere with the patient’s optimal participation in the study; 13. Currently participating in an investigational drug or another device study that has not completed the primary endpoint, or subject to inclusion in another investigational drug or another device study during follow-up of this study; 14. Patients currently undergoing chemotherapy or immunosuppressant therapy; 15. Patients with known malignancy(ies). Angiographic exclusion criteria: 16. Unprotected left main coronary artery disease with 50% stenosis; 17. Ostial target lesion; 18. Totally occluded target vessel (TIMI flow 0); 19. Target lesion has excessive tortuousity unsuitable for stent delivery and deployment; 20. Target lesion involves bifurcation class D & type G including a side branch 2.5mm in diameter (either stenosis of both main vessel and major side branch or stenosis of just major side branch) that would require stenting of diseased side branch; 21. Angiographic evidence of thrombus in the target vessel; 22. A significant (> 50%) stenosis proximal or distal to the target lesion; 23. Impaired runoff in the treatment vessel with diffuse distal disease; 24. Left Ventricular ejection fraction 30%; Other exclusion criteria: 25. Pre-treatment with devices other than balloon angioplasty, although direct stenting is allowed; 26. Prior stent within 5mm of target lesion; 27. Intervention of another lesion within 6 months prior to or after the index procedure.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this study is mean coronary segment diameter change from baseline after maximal endothelium-dependent vasomotion at 6 months post-procedure. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
After the 12 month follow up contact |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |